Effectiveness of Fingolimod versus Natalizumab as Second-Line Therapy for Relapsing-Remitting Multiple Sclerosis in Spain: Second-Line GATE Study Academic Article 2020 uri icon

authors

  • Meca-Lallana J
  • Meca-Lallana V
  • Romero Sevilla R
  • Ricart J
  • Ayuso T
  • Martínez-Yelamos S
  • Durán C
  • Contreras Martín Y
  • Herrera Navarro N
  • PEREZ SEMPERE, ANGEL CONSTANTINO
  • Álvarez-Cermeño JC
  • Millán Pascual J

publication date

  • 2020